ArticleCancer biomarkers : section A of Disease markers2022
The impact of the lung EDRN-CVC on Phase 1, 2, & 3 biomarker validation studies.
Michael N Kammer et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it